Generate a tailored SOP for Dr. Mary Rinella. Improve your application with a focused, well-structured draft.
Mary E. Rinella is a professor in the Department of Medicine at the University of Chicago, where she has been since January 2021. She serves as the director of the Metabolic Fatty Liver Program and the clinical trials section. Dr. Rinella has held numerous national societal leadership roles, including serving on the Governing Board of the American Association for the Study of Liver Disease (AASLD). Notably, she was the lead author for the 2023 AASLD Clinical Practice Guidance on the diagnosis and management of Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Furthermore, she chaired the AASLD Steatotic Liver Disease task force, which focuses on increasing awareness of the disease and creating a national strategy for global collaboration to improve patient care. Her clinical research specializes in metabolic liver diseases, with significant expertise in cholestatic liver diseases, including Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC), as well as complications associated with cirrhosis and portal hypertension.
Department of Philosophy